近日,跨国巨头强生(Johnson & Johnson)宣布了一项重大并购交易,以146亿美元收购了精神分裂症药物研发公司Intra-Cellular Therapies。这笔交易是近两年以来生物科技行业最大的一笔交易,也是2024年以来首笔过百亿美元并购的案例。高达146亿美元(折合人民币约1070亿元)的交易价格,直接超过了药明生物近期港股市值(约720亿港元)。对此有投资者表示:药明生物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.